Pantheon International PLC (PIP) said it believes investor concerns about the private equity sector are “excessive” as its portfolio held up in the first half of its financial year but its share price widened to a 42% discount to net asset value (NAV).
The FTSE 250 investment trust's NAV per share grew 4% to 469.5p in the six months to end-November 2022, up 11.5% over one year or 18.8% over three years.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) has said it aims to produce between 50,000 and 54,000 gold equivalent ounces in full-year 2023 (FY 2023), comprising 4,100 to 4,300 tonnes of copper and 30,000 to 32,000 ounces of gold.
The AIM-listed gold, copper, and silver producer based in Azerbaijan said the production guidance for FY 2023 includes 43,114 ounces of gold, 2,516 tonnes of copper, and 57,618 gold equivalent ounces. The gold equivalent ounces have been computed based on the budget rates, which incorporate the price of metal and the weight of metal equivalent to one ounce of gold, it added.
Quadrise Fuels International PLC (AIM:QFI, OTC:QDRSF) said both its MSAR and bioMSAR heavy oil have cleared customs in Morocco and are now on-site with its client.
The bioMSAR was delivered in December and the company today said the MSAR has now also cleared customs.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) will work with neighbour Noble Helium to source and secure a suitable drilling rig for both their operations in Tanzania's Rukwa Basin.
The AIM-listed company said it has entered into a cooperation agreement with the ASX-listed outfit, where the pair will also arrange associated services and logistics required for its planned drilling campaign.
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) has appointed Dr Jay Pepose, founder and medical director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to its Scientific Advisory Board (SAB).
Pepose, a renowned ophthalmologist with expertise in the medical and surgical treatment of ocular surface diseases, will play a pivotal role in guiding OKYO's clinical programme for its dry eye disease (DED) treatment, OK-101. The company plans to open its phase II trial of OK-101 to enrolment this quarter.
Metal Tiger PLC (AIM:MTR, OTC:MRTTF, ASX:MTR) noted portfolio company Sothern Gold, in which it holds a 19.1% interest, has begun drilling operations its main Deokon Mine in South Korea, kicking off the first project there in 40 years.